GPR160与前列腺癌相关性首次得以揭示
发布时间：2019-06-06 12:23
【摘要】：正中科院上海药物研究所国家新药筛选中心王明伟课题组与丁健课题组合作,首次揭示了GPR160与前列腺癌的相关性,为靶向GPR160的抗前列腺癌药物发现奠定了基础。相关研究成果已在线发表于《肿瘤靶点》。据悉,G蛋白偶联受体(GPCR)是目前最为成功的药物靶标家族,其在肿瘤发生和发展过程中的作用日益受到关注。
[Abstract]:Wang Mingwei, National Drug screening Center of Shanghai Institute of Medicine, Chinese Academy of Sciences, worked with Ding Jian to reveal the correlation between GPR160 and prostate cancer for the first time, which laid a foundation for the discovery of anti-prostate cancer drugs targeting GPR160. The related research results have been published online in tumor Target. It is reported that G protein-coupled receptor (GPCR) is the most successful drug target family at present, and its role in tumorigenesis and development has been paid more and more attention.
【分类号】：R737.25
，
本文编号：2494362
[Abstract]:Wang Mingwei, National Drug screening Center of Shanghai Institute of Medicine, Chinese Academy of Sciences, worked with Ding Jian to reveal the correlation between GPR160 and prostate cancer for the first time, which laid a foundation for the discovery of anti-prostate cancer drugs targeting GPR160. The related research results have been published online in tumor Target. It is reported that G protein-coupled receptor (GPCR) is the most successful drug target family at present, and its role in tumorigenesis and development has been paid more and more attention.
【分类号】：R737.25
，
本文编号：2494362
本文链接：https://www.wllwen.com/yixuelunwen/mjlw/2494362.html
最近更新
教材专著
